Meeting
2023 ASCO Breakthrough
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in RATIONALE-301 population.
Authors
Richard S. Finn
Department of Medicine, Division of Hematology/Oncology, University of California Los Angeles, Los Angeles, CA
Richard S. Finn , Shukui Qin , Masatoshi Kudo , Tim Meyer , Frederic Boisserie , Songzi Li , Yaxi Chen , Gisoo Barnes , Ramil Abdrashitov , Andrew X. Zhu , Arndt Vogel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Gastrointestinal Cancer,Gynecologic Cancer,Head and Neck Cancer,Quality of Care,Genetics/Genomics/Multiomics,Healthcare Equity and Access to Care,Healthtech Innovations,Models of Care and Care Delivery,Population Health,Viral-Mediated Malignancies
Sub Track
Immunotherapies
Clinical Trial Registration Number
NCT03412773
Citation
JCO Global Oncology 9, 2023 (suppl 1; abstr 43)
DOI
10.1200/GO.2023.9.Supplement_1.43
Abstract #
43
Poster Bd #
B10
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in RATIONALE-301 population.
First Author: Richard S. Finn
Poster
2023 ASCO Annual Meeting
Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): The RATIONALE-301 European/North American (EU/NA) subgroup.
First Author: Arndt Vogel
Poster
2023 ASCO Annual Meeting
Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS).
First Author: Masatoshi Kudo
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Patient-reported outcomes (PROs) <65 or ≥ 65 years old (yo) from CARES-310 camrelizumab + rivoceranib vs sorafenib as first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC).
First Author: Stephen Lam Chan